January 24, 2024 11:03 AM EST
Manufacturing

De­spite CD­MO head­winds, Sam­sung Bio re­ports 2023 rev­enue jump and pre­dicts even more gains this year

Anna Brown

News Reporter

Sam­sung Bi­o­log­ics said on Wednes­day that it de­liv­ered “ex­cep­tion­al” rev­enue growth in 2023 and pre­dicts an in­crease this year, which coun­ters mut­ed re­ports by oth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times